High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses |
| |
| Institution: | 1. Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA;2. Vanderbilt University Medical Center, A2200 MCN, 1161 21st Ave. South, Nashville, TN 37232, USA;3. Batelle Memorial Institute, 2987 Clairmont Road, Suite 450, Atlanta, GA 30329, USA;1. Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA;2. Battelle Memorial Institute, Atlanta, GA, USA;3. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA;4. Virus, Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA;1. Faculty of Veterinary Medicine, Tehran University, P.O. Box 14155-6453, Tehran, Iran;2. Razi Vaccine & Serum Research Institute, Agricultural Research Education and Extension Organization, P.O. Box 31975-148, Karaj, Iran;1. Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA;2. Keck School of Medicine, University of Southern California, Los Angeles, USA;3. The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA;4. Department of Medicine, University of California Los Angeles, Los Angeles, USA;5. Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, USA;6. Abbott Diagnostics, Abbott Park, USA;1. Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy;2. Microbiology and Virology Unit, Dermatological Clinical Department, IRCCS San Gallicano Dermatological Institute, Rome, Italy;3. Department of Clinical and Molecular Medicine, Università La Sapienza di Roma, Rome, Italy;4. Biostatistic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy;1. Department of Pathology, Albert Einstein College of Medicine, Bronx, NY;2. Division of Newborn Medicine, Harvard Medical School, Boston, MA;3. Division of Respiratory Diseases, Children''s Hospital, Harvard Medical School, Boston, MA |
| |
| Abstract: | High-dose (HD) influenza vaccine shows improved relative efficacy against influenza disease compared to standard-dose (SD) vaccine in individuals ?65 years. This has been partially credited to superior serological responses, but a comprehensive understanding of cell-mediated immunity (CMI) of HD vaccine remains lacking. In the current study, a total of 105 participants were randomly administered HD or SD vaccine and were evaluated for serological responses. Subsets of the group (n = 12–26 per group) were evaluated for B and T cell responses at days 0, 7, 14 and 28 post-vaccination by flow cytometry or ELISPOT assay. HD vaccine elicited significantly higher hemagglutination inhibition (HI) titers than SD vaccine at d28, but comparable titers at d365 post-vaccination. HD vaccine also elicited higher vaccine-specific plasmablast responses at d7 post-vaccination than SD vaccine. However, long-lived memory B cell induction, cytokine-secreting T cell responses and persistence of serological memory were comparable regardless of vaccine dose. More strategies other than increased Ag amount may be needed to improve CMI in older adults.Trial Registration: ClinicalTrials.gov NCT 01189123 |
| |
| Keywords: | High-dose influenza vaccine Cell-mediated immunity Plasmablast response Older adults |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
